Mitral Valve Interventions in Structural Heart Disease

  • Matteo Saccocci
  • Maurizio Taramasso
  • Francesco Maisano
Structural Heart Disease (RJ Siegel and NC Wunderlich, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Structural Heart Disease


Purpose of review

Analyze the current state of the art and the future perspectives of mitral interventions in clinical setting.

Recent Findings

A systematic and critical review of the new mitral percutaneous therapies and imaging technologies is the basis to adopt the right treatment for each patient according to specific valve dysfunction and clinical presentation, waiting for definitive guidelines. While surgical mitral repair will remain the gold standard for low-risk healthy patients with degenerative mitral regurgitation (DMR), transcatheter mitral valve repair is becoming first line therapy in high risk patients with functional mitral regurgitation (FMR). The introduction of transcatheter mitral valve replacement will expand indications for advanced DMR and FMR in inoperable patients.


The introduction of transcatheter mitral interventions is changing the mitral therapy scenario. Mitral interventionalists might evolve into hybrid professional figures able to offer a tailored approach for each patient, including surgical and percutaneous approaches, depending on the anatomo-functional status of the valve, to clinical conditions, and to the timing of the intervention.


Mitral regurgitation TMVREP TMVI Structural heart disease Transcatheter mitral valve interventions 



MWT 6 minutes walking test


Degenerative Mitral Regurgitation


Left ventricular ejection fraction


Minnesota Living with Heart Failure questionnaire


Mitral valve repair


New York Heart Association




Transcatheter mitral valve implantation


Transcatheter mitral valve repair


Compliance with Ethical Standards

Conflict of Interest

Matteo Saccocci has no conflicts of interest to declare.

Maurizio Taramasso is a consultant for Abbott Vascular and 4Tech Cardio, and Boston Scientific.

Francesco Maisano is a consultant for Abbot Vascular, Edwards Lifesciences, ValtechCArdio, Mitraltech, Medtronic, St. Jude, and Xeltis. He is the co-founder and a shareholder of 4Tech Cardio, TransSePtalsolutions, and Affix. He receives royalties from Edwards Lifesciences and grants from Abbott, St. Jude Medical, Bioventrix, and DirectFlow. He has the following patents: Deployment techniques for annuloplasty ring and overwire rotation; Tool retaining mechanisms for prosthetic valves WO2009155561 (A2); Deployment techniques for annuloplasty ring and overwire rotation tool EP2427145 (A2); Implantation of repair chords in the heart EP2427144 (A1); Method and apparatus for tricuspid valve repair using tension US2012035712 (A1); Annuloplasty Rings for Repair of Abnormal Mitral Valves US2011301704 (A1); Delivery tool for implantation of spool assembly coupled to a helical anchor US2011282361 (A1); Tricuspid valve repair using tension US2011184510 (A1); Retaining mechanisms for prosthetic valves EP2303190 (A2); Retaining Mechanisms for Prosthetic Valves US2010256751 (A1); Annular Prosthesis for a Mitral Valve US2010137980 (A1); Adjustable repair chords and spool mechanism therefor US2010161041 (A1); Dispositivo per uso in emodinamica ITMI20070906 (A1); Mezzo per vedere una valvola cardiaca in fase intraoperatoria ITMI20060963 (A1); Annuloplasty rings for repair of abnormal mitral valves WO2005034813 (A2).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and Stroke Statistics-2017 Update: a Report From the American Heart Association. Circulation. 2017;135(10):e146–603.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005–11.CrossRefPubMedGoogle Scholar
  3. 3.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2017.Google Scholar
  4. 4.
    • Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart diseaseThe Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2017. The latest international guidelines establish the new level of indications for percutaneous mitral valve treatment. Google Scholar
  5. 5.
    Mirabel M, Iung B, Baron G, Messika-Zeitoun D, Detaint D, Vanoverschelde JL, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28(11):1358–65.CrossRefPubMedGoogle Scholar
  6. 6.
    Maisano F, Kuwata S, Nietlispach F, Taramasso M. Transcatheter mitral valve repair and replacement. J Cardiovasc Med (Hagerstown). 2017;18 Suppl 1: Special Issue on The State of the Art for the Practicing Cardiologist: The 2016 Conoscere E Curare Il Cuore (CCC) Proceedings from the CLI Foundation:e134–e40.Google Scholar
  7. 7.
    Taramasso M, Kuwata S. Rodriguez Cetina Biefer H, Nietlispach F, Maisano F. Percutaneous mitral valve repair and replacement: complementary or competitive techniques? EuroIntervention. 2016;12(Y):Y97–y101.CrossRefPubMedGoogle Scholar
  8. 8.
    Alfieri O, Maisano F, De Bonis M, Stefano PL, Torracca L, Oppizzi M, et al. The double-orifice technique in mitral valve repair: a simple solution for complex problems. J Thorac Cardiovasc Surg. 2001;122(4):674–81.CrossRefPubMedGoogle Scholar
  9. 9.
    Maisano F, Torracca L, Oppizzi M, Stefano PL, D'Addario G, La Canna G, et al. The edge-to-edge technique: a simplified method to correct mitral insufficiency. Eur J Cardiothorac Surg. 1998;13(3):240–5. Discussion 5–6CrossRefPubMedGoogle Scholar
  10. 10.
    Attizzani GF, Ohno Y, Capodanno D, Cannata S, Dipasqua F, Imme S, et al. Extended use of percutaneous edge-to-edge mitral valve repair beyond EVEREST (Endovascular Valve Edge-to-Edge Repair) criteria: 30-day and 12-month clinical and echocardiographic outcomes from the GRASP (Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation) registry. JACC Cardiovasc Interv. 2015;8(1 Pt A):74–82.CrossRefPubMedGoogle Scholar
  11. 11.
    Feldman T, Kar S, Elmariah S, Smart SC, Trento A, Siegel RJ, et al. Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II. J Am Coll Cardiol. 2015;66(25):2844–54.CrossRefPubMedGoogle Scholar
  12. 12.
    Cardiac Interventions Today - The EVEREST Percutaneous Mitral Leaflet Repair Trials. Cardiac Interventions Today. 2011;september/october 2011.Google Scholar
  13. 13.
    Alice Perlowski TEF. The EVEREST Percutaneous Mitral Leaflet Repair Trials: An overview of the safety and efficacy data of the MitraClip system for treating mitral regurgitation. Cardiac Interventions Today. 2011;September/October 2011.Google Scholar
  14. 14.
    Mauri L, Garg P, Massaro JM, Foster E, Glower D, Mehoudar P, et al. The EVEREST II Trial: design and rationale for a randomized study of the evalve mitraclip system compared with mitral valve surgery for mitral regurgitation. Am Heart J. 2010;160(1):23–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Feldman T, Wasserman HS, Herrmann HC, Gray W, Block PC, Whitlow P, et al. Percutaneous mitral valve repair using the edge-to-edge technique: 6-month results of the EVEREST Phase I Clinical Trial. J Am Coll Cardiol. 2005;46(11):2134–40.CrossRefPubMedGoogle Scholar
  16. 16.
    Maisano F, Franzen O, Baldus S, Schafer U, Hausleiter J, Butter C, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol. 2013;62(12):1052–61.CrossRefPubMedGoogle Scholar
  17. 17.
    Puls M, Lubos E, Boekstegers P, von Bardeleben RS, Ouarrak T, Butter C, et al. One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry. Eur Heart J. 2016;37:703–12.CrossRefPubMedGoogle Scholar
  18. 18.
    Wiebe J, Franke J, Lubos E, Boekstegers P, Schillinger W, Ouarrak T, et al. Percutaneous mitral valve repair with the MitraClip system according to the predicted risk by the logistic EuroSCORE: preliminary results from the German Transcatheter Mitral Valve Interventions (TRAMI) Registry. Catheter Cardiovasc Interv. 2014;84(4):591–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Schwencke C, Bijuklic K, Ouarrak T, Lubos E, Schillinger W, Plicht B, et al. Impact of cardiac comorbidities on early and 1-year outcome after percutaneous mitral valve interventions: data from the German transcatheter mitral valve interventions (TRAMI) registry. Clin Res Cardiol. 2017;106(4):249–58.CrossRefPubMedGoogle Scholar
  20. 20.
    Eggebrecht H, Schelle S, Puls M, Plicht B, von Bardeleben RS, Butter C, et al. Risk and outcomes of complications during and after MitraClip implantation: Experience in 828 patients from the German TRAnscatheter mitral valve interventions (TRAMI) registry. Catheter Cardiovasc Interv. 2015;86(4):728–35.CrossRefPubMedGoogle Scholar
  21. 21.
    Schueler R, Nickenig G, May AE, Schillinger W, Bekeredjian R, Ouarrak T, et al. Predictors for short-term outcomes of patients undergoing transcatheter mitral valve interventions: analysis of 778 prospective patients from the German TRAMI registry focusing on baseline renal function. EuroIntervention. 2016;12(4):508–14.CrossRefPubMedGoogle Scholar
  22. 22.
    Schillinger W, Hunlich M, Baldus S, Ouarrak T, Boekstegers P, Hink U, et al. Acute outcomes after MitraClip therapy in highly aged patients: results from the German TRAnscatheter Mitral valve Interventions (TRAMI) Registry. EuroIntervention. 2013;9(1):84–90.CrossRefPubMedGoogle Scholar
  23. 23.
    Schillinger W, Senges J. TRAMI (Transcatheter Mitral Valve Interventions) register. The German mitral register. Herz. 2013;38(5):453–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Kalbacher D, Schafer U, von Bardeleben RS, Zuern CS, Bekeredjian R, Ouarrak T, et al. Impact of tricuspid valve regurgitation in surgical high-risk patients undergoing MitraClip implantation: results from the TRAMI registry. EuroIntervention. 2017;12(15):e1809–e16.CrossRefPubMedGoogle Scholar
  25. 25.
    Geis NA, Puls M, Lubos E, Zuern CS, Franke J, Schueler R, et al. Safety and efficacy of MitraClip therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail. 2017.Google Scholar
  26. 26.
    Baldus S, Schillinger W, Franzen O, Bekeredjian R, Sievert H, Schofer J, et al. MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail. 2012;14(9):1050–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Arnold SV, Reynolds MR, Lei Y, Magnuson EA, Kirtane AJ, Kodali SK, et al. Predictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER (Placement of Aortic Transcatheter Valve) trial. Circulation. 2014;129(25):2682–90.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Gafoor S, Sievert H, Maisano F, Baldus S, Schaefer U, Hausleiter J, et al. Gender in the ACCESS-EU registry: a prospective, multicentre, non-randomised post-market approval study of MitraClip(R) therapy in Europe. EuroIntervention. 2016;12(2):e257–64.CrossRefPubMedGoogle Scholar
  29. 29.
    Reichenspurner H, Schillinger W, Baldus S, Hausleiter J, Butter C, Schaefer U, et al. Clinical outcomes through 12 months in patients with degenerative mitral regurgitation treated with the MitraClip(R) device in the ACCESS-EUrope Phase I trial. Eur J Cardiothorac Surg. 2013;44(4):e280–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Schafer U, Maisano F, Butter C, Franzen O, Baldus S, Hausleiter J, et al. Impact of Preprocedural Left Ventricular Ejection Fraction on 1-Year Outcomes After MitraClip Implantation (from the ACCESS-EU Phase I, a prospective, multicenter, nonrandomized postapproval study of the mitraclip therapy in Europe). Am J Cardiol. 2016;118(6):873–80.CrossRefPubMedGoogle Scholar
  31. 31.
    Praz F, Spargias K, Chrissoheris M, Bullesfeld L, Nickenig G, Deuschl F, et al. Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. Lancet. 2017;390(10096):773–80.CrossRefPubMedGoogle Scholar
  32. 32.
    Carpentier A. Cardiac valve surgery--the "French correction". J Thorac Cardiovasc Surg. 1983;86(3):323–37.PubMedGoogle Scholar
  33. 33.
    Kiefer P, Seeburger J. The potential of transapical beating-heart mitral valve repair with neo-chordae. Ann Transl Med. 5; 2017.Google Scholar
  34. 34.
    Seeburger J, Rinaldi M, Nielsen SL, Salizzoni S, Lange R, Schoenburg M, et al. Off-pump transapical implantation of artificial neo-chordae to correct mitral regurgitation: the TACT Trial (Transapical Artificial Chordae Tendinae) proof of concept. J Am Coll Cardiol. 2014;63(9):914–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Colli A, Manzan E, Zucchetta F, Bizzotto E, Besola L, Bagozzi L, et al. Transapical off-pump mitral valve repair with Neochord implantation: early clinical results. Int J Cardiol. 2016;204:23–8.CrossRefPubMedGoogle Scholar
  36. 36.
    A. C. Transapical Off-Pump Mitral valve repair with Neochord Implantation: clinical update at EuroPCR 2015. EuroPCR2015;2015.Google Scholar
  37. 37.
    V. Gil Ad GG, E. Amoncelli, A. Albertini, K. Fattouch, L. Bardaro, A. Barosi, G. Speziali, L. Martinelli. Transapical off-pump mitral valve repair with neochord implantation: first year results in a multicentric experience. EuroPCR 2017: EuroPCR 2017; 2017.Google Scholar
  38. 38.
    Gammie JS, Wilson P, Bartus K, Gackowski A, Hung J, D'Ambra MN, et al. Transapical beating-heart mitral valve repair with an expanded polytetrafluoroethylene cordal implantation device: initial clinical experience. Circulation. 2016;134(3):189–97.CrossRefPubMedGoogle Scholar
  39. 39.
    De Bonis M, Lapenna E, Maisano F, Barili F, La Canna G, Buzzatti N, et al. Long-term results (</ = 18 years) of the edge-to-edge mitral valve repair without annuloplasty in degenerative mitral regurgitation: implications for the percutaneous approach. Circulation. 2014;130(11 Suppl 1):S19–24.CrossRefPubMedGoogle Scholar
  40. 40.
    Kuwata S, Taramasso M, Guidotti A, Nietlispach F, Maisano F. Ongoing and future directions in percutaneous treatment of mitral regurgitation. Expert Rev Cardiovasc Ther. 2017;15(6):441–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Taramasso M, Inderbitzin DT, Guidotti A, Nietlispach F, Gaemperli O, Zuber M, et al. Transcatheter direct mitral valve annuloplasty with the Cardioband system for the treatment of functional mitral regurgitation. Multimed Man Cardiothorac Surg. 2016.
  42. 42.
    Nickenig G, Hammerstingl C, Schueler R, Topilsky Y, Grayburn PA, Vahanian A, et al. Transcatheter mitral annuloplasty in chronic functional mitral regurgitation: 6-month results with the Cardioband percutaneous mitral repair system. JACC Cardiovasc Interv. 2016;9(19):2039–47.CrossRefPubMedGoogle Scholar
  43. 43.
    F M. Clinical experience with Edwards Cardioband system for mitral regurgitation. EuroPCR2017 congress: EuroPCR2017 congress; 2017.Google Scholar
  44. 44.
    Schueler R, Nickenig G. The Mitralign: strategies for optimal patient selection and optimised results. EuroIntervention. 2016;12(Y):Y67–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Nickenig G, Schueler R, Dager A, Martinez Clark P, Abizaid A, Siminiak T, et al. Treatment of chronic functional mitral valve regurgitation with a Percutaneous Annuloplasty System. J Am Coll Cardiol. 2016;67(25):2927–36.CrossRefPubMedGoogle Scholar
  46. 46.
    Schofer J, Siminiak T, Haude M, Herrman JP, Vainer J, Wu JC, et al. Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study. Circulation. 2009;120(4):326–33.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Siminiak T, Wu JC, Haude M, Hoppe UC, Sadowski J, Lipiecki J, et al. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. Eur J Heart Fail. 2012;14(8):931–8.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Bail DH. Treatment of functional mitral regurgitation by percutaneous annuloplasty using the Carillon Mitral Contour System-Currently available data state. J Interv Cardiol. 2017;30(2):156–2.Google Scholar
  49. 49.
    De Bonis M, Lapenna E, La Canna G, Ficarra E, Pagliaro M, Torracca L, et al. Mitral valve repair for functional mitral regurgitation in end-stage dilated cardiomyopathy: role of the "Edge-to-Edge" technique. Circulation. 2005;112(9 Suppl):I402–8.PubMedGoogle Scholar
  50. 50.
    Latib A, Ancona MB, Ferri L, Montorfano M, Mangieri A, Regazzoli D, et al. Percutaneous direct annuloplasty with Cardioband to treat recurrent mitral regurgitation after MitraClip implantation. JACC Cardiovasc Interv. 2016;9(18):e191–2.CrossRefPubMedGoogle Scholar
  51. 51.
    FM. A new solution to the old problem of functional mitral regurgitation. PCR London Valves 2017; London 2017.Google Scholar
  52. 52.
    Bardeleben V. Featured lecture: MitraClip and other transcatheter mitral valve therapies for function MR: a "sensible" multi-device treatment algorithm. TVT Congress 2017; 2017.Google Scholar
  53. 53.
    VonBardeleben. Rationale for and case examples of combination Transcatheter Mitral Annuloplasty and Edge-to-Edge procedures. TCT Congress 2016; 2016.Google Scholar
  54. 54.
    FM. Cardioband implantation to treat recurrent mitral regurgitation due to annular dilatation after MitraClip – toward a surgical standard. TvT Congress 2016; 2016.Google Scholar
  55. 55.
    Regueiro A, Granada JF, Dagenais F, Rodes-Cabau J. Transcatheter mitral valve replacement: insights from early clinical experience and future challenges. J Am Coll Cardiol. 2017;69(17):2175–92.CrossRefPubMedGoogle Scholar
  56. 56.
    Sondergaard L, Brooks M, Ihlemann N, Jonsson A, Holme S, Tang M, et al. Transcatheter mitral valve implantation via transapical approach: an early experience. Eur J Cardiothorac Surg. 2015;48(6):873–7. Discussion 7–8CrossRefPubMedGoogle Scholar
  57. 57.
    Barbanti M, Tamburino C. Transcatheter mitral valve implantation: CardiAQ. EuroIntervention. 2016;12(Y):Y73–4.CrossRefPubMedGoogle Scholar
  58. 58.
    Ussia GP, Quadri A, Cammalleri V, De Vico P, Muscoli S, Marchei M, et al. Percutaneous transfemoral-transseptal implantation of a second-generation CardiAQ mitral valve bioprosthesis: first procedure description and 30-day follow-up. EuroIntervention. 2016;11(10):1126–31.CrossRefPubMedGoogle Scholar
  59. 59.
    Sondergaard L, Ussia GP, Dumonteil N, Quadri A. The CardiAQ transcatheter mitral valve implantation system. EuroIntervention. 2015;11(Suppl W):W76–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Sondergaard L, De Backer O, Franzen OW, Holme SJ, Ihlemann N, Vejlstrup NG, et al. First-in-Human Case of Transfemoral CardiAQ Mitral Valve Implantation. Circ Cardiovasc Interv. 2015;8(7):e002135.CrossRefPubMedGoogle Scholar
  61. 61.
    Meredith I, Bapat V, Morriss J, McLean M, Prendergast B. Intrepid transcatheter mitral valve replacement system: technical and product description. EuroIntervention. 2016;12(Y):Y78–80.CrossRefPubMedGoogle Scholar
  62. 62.
    Muller DW, Farivar RS, Jansz P, Bae R, Walters D, Clarke A, et al. Transcatheter mitral valve replacement for patients with symptomatic mitral regurgitation: a Global Feasibility Trial. J Am Coll Cardiol. 2017;69(4):381–91.CrossRefPubMedGoogle Scholar
  63. 63.
    Quarto C, Davies S, Duncan A, Lindsay A, Lutter G, Lozonschi L, et al. Transcatheter mitral valve implantation: 30-day outcome of first-in-man experience with an apically tethered device. Innovations (Phila). 2016;11(3):174–8.CrossRefPubMedGoogle Scholar
  64. 64.
    Perpetua EM, Reisman M. The Tendyne transcatheter mitral valve implantation system. EuroIntervention. 2015;11(Suppl W):W78–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Cheung A, Webb J, Verheye S, Moss R, Boone R, Leipsic J, et al. Short-term results of transapical transcatheter mitral valve implantation for mitral regurgitation. J Am Coll Cardiol. 2014;64(17):1814–9.CrossRefPubMedGoogle Scholar
  66. 66.
    Verheye S, Cheung A, Leon M, Banai S. The Tiara transcatheter mitral valve implantation system. EuroIntervention. 2015;11(Suppl W):W71–2.CrossRefPubMedGoogle Scholar
  67. 67.
    Lange R, Piazza N. HighLife transcatheter mitral valve replacement. EuroIntervention. 2016;12(Y):Y81–3.CrossRefPubMedGoogle Scholar
  68. 68.
    Desai MY, Grigioni F, Di Eusanio M, Saccocci M, Taramasso M, Maisano F, et al. Outcomes in degenerative mitral regurgitation: current state-of-the art and future directions. Prog Cardiovasc Dis. 2017;60(3):370–85.CrossRefPubMedGoogle Scholar
  69. 69.
    Franzen O, Baldus S, Rudolph V, Meyer S, Knap M, Koschyk D, et al. Acute outcomes of MitraClip therapy for mitral regurgitation in high-surgical-risk patients: emphasis on adverse valve morphology and severe left ventricular dysfunction. Eur Heart J. 2010;31(11):1373–81.CrossRefPubMedGoogle Scholar
  70. 70.
    Auricchio A, Schillinger W, Meyer S, Maisano F, Hoffmann R, Ussia GP, et al. Correction of mitral regurgitation in nonresponders to cardiac resynchronization therapy by MitraClip improves symptoms and promotes reverse remodeling. J Am Coll Cardiol. 2011;58(21):2183–9.CrossRefPubMedGoogle Scholar
  71. 71.
    Pleger ST, Mereles D, Schulz-Schonhagen M, Krumsdorf U, Chorianopoulos E, Rottbauer W, et al. Acute safety and 30-day outcome after percutaneous edge-to-edge repair of mitral regurgitation in very high-risk patients. Am J Cardiol. 2011;108(10):1478–82.CrossRefPubMedGoogle Scholar
  72. 72.
    Paranskaya L, D'Ancona G, Bozdag-Turan I, Akin I, Kische S, Turan GR, et al. Early and mid-term outcomes of percutaneous mitral valve repair with the MitraClip(R): comparative analysis of different EuroSCORE strata. EuroIntervention. 2012;8(5):571–8.CrossRefPubMedGoogle Scholar
  73. 73.
    Treede H, Schirmer J, Rudolph V, Franzen O, Knap M, Schluter M, et al. A heart team's perspective on interventional mitral valve repair: percutaneous clip implantation as an important adjunct to a surgical mitral valve program for treatment of high-risk patients. J Thorac Cardiovasc Surg. 2012;143(1):78–84.CrossRefPubMedGoogle Scholar
  74. 74.
    Van den Branden BJ, Swaans MJ, Post MC, Rensing BJ, Eefting FD, Jaarsma W, et al. Percutaneous edge-to-edge mitral valve repair in high-surgical-risk patients: do we hit the target? JACC Cardiovasc Interv. 2012;5(1):105–11.CrossRefPubMedGoogle Scholar
  75. 75.
    Armoiry X, Brochet E, Lefevre T, Guerin P, Dumonteil N, Himbert D, et al. Initial French experience of percutaneous mitral valve repair with the MitraClip: a multicentre national registry. Arch Cardiovasc Dis. 2013;106(5):287–94.CrossRefPubMedGoogle Scholar
  76. 76.
    Grasso C, Capodanno D, Scandura S, Cannata S, Imme S, Mangiafico S, et al. One- and 12-month safety and efficacy outcomes of patients undergoing edge-to-edge percutaneous mitral valve repair (from the GRASP Registry). Am J Cardiol. 2013;111(10):1482–7.CrossRefPubMedGoogle Scholar
  77. 77.
    Surder D, Pedrazzini G, Gaemperli O, Biaggi P, Felix C, Rufibach K, et al. Predictors for efficacy of percutaneous mitral valve repair using the MitraClip system: the results of the MitraSwiss registry. Heart. 2013;99(14):1034–40.CrossRefPubMedGoogle Scholar
  78. 78.
    Edelman JJ, Dias P, Passage J, Yamen E. Percutaneous mitral valve repair in a high-risk Australian series. Heart Lung Circ. 2014;23(6):520–6.CrossRefPubMedGoogle Scholar
  79. 79.
    Taramasso M, Maisano F, Latib A, Denti P, Buzzatti N, Cioni M, et al. Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation. EuroIntervention. 2014;10(6):746–52.CrossRefPubMedGoogle Scholar
  80. 80.
    Yeo KK, Yap J, Yamen E, Muda N, Tay E, Walters DL, et al. Percutaneous mitral valve repair with the MitraClip: early results from the MitraClip Asia-Pacific Registry (MARS). EuroIntervention. 2014;10(5):620–5.CrossRefPubMedGoogle Scholar
  81. 81.
    Pighi M, Estevez-Loureiro R, Maisano F, Ussia GP, Dall'Ara G, Franzen O, et al. Immediate and 12-month outcomes of ischemic versus nonischemic functional mitral regurgitation in patients treated With MitraClip (from the 2011 to 2012 Pilot Sentinel Registry of Percutaneous Edge-to-Edge Mitral Valve Repair of the European Society of Cardiology). Am J Cardiol. 2017;119(4):630–7.CrossRefPubMedGoogle Scholar
  82. 82.
    Panaich SS, Arora S, Badheka A, Kumar V, Maor E, Raphael C, et al. Procedural trends, outcomes, and readmission rates pre-and post-FDA approval for MitraClip from the National Readmission Database (2013–14). Catheter Cardiovasc Interv. 2017;Google Scholar
  83. 83.
    Hayashida K, Yasuda S, Matsumoto T, Amaki M, Mizuno S, Tobaru T, et al. AVJ-514 Trial- baseline characteristics and 30-day outcomes following MitraClip((R)) treatment in a Japanese cohort. Circ J. 2017;81(8):1116–22.CrossRefPubMedGoogle Scholar
  84. 84.
    Sorajja P, Vemulapalli S, Feldman T, Mack M, Holmes DR Jr, Stebbins A, et al. Outcomes With Transcatheter Mitral Valve Repair in the United States: a STS/ACC TVT Registry Report. J Am Coll Cardiol. 2017;70(19):2315–27.CrossRefPubMedGoogle Scholar
  85. 85.
    Paranskaya L, D'Ancona G, Bozdag-Turan I, Akin I, Kische S, Turan GR, et al. Residual mitral valve regurgitation after percutaneous mitral valve repair with the MitraClip(R) system is a risk factor for adverse 1-year outcome. Catheter Cardiovasc Interv. 2013;81(4):609–17.CrossRefPubMedGoogle Scholar
  86. 86.
    Grayburn PA, Foster E, Sangli C, Weissman NJ, Massaro J, Glower DG, et al. Relationship between the magnitude of reduction in mitral regurgitation severity and left ventricular and left atrial reverse remodeling after MitraClip therapy. Circulation. 2013;128(15):1667–74.CrossRefPubMedGoogle Scholar
  87. 87.
    Eleid MF, Reeder GS, Malouf JF, Lennon RJ, Pislaru SV, Nkomo VT, et al. The learning curve for transcatheter mitral valve repair with MitraClip. J Interv Cardiol. 2016;29(5):539–45.CrossRefPubMedGoogle Scholar
  88. 88.
    Schillinger W, Athanasiou T, Weicken N, Berg L, Tichelbacker T, Puls M, et al. Impact of the learning curve on outcomes after percutaneous mitral valve repair with MitraClip and lessons learned after the first 75 consecutive patients. Eur J Heart Fail. 2011;13(12):1331–9.CrossRefPubMedGoogle Scholar
  89. 89.
    Gammie JS, O'Brien SM, Griffith BP, Ferguson TB, Peterson ED. Influence of hospital procedural volume on care process and mortality for patients undergoing elective surgery for mitral regurgitation. Circulation. 2007;115(7):881–7.CrossRefPubMedGoogle Scholar
  90. 90.
    Nishimura RA, Vahanian A, Eleid MF, Mack MJ. Mitral valve disease – current management and future challenges. Lancet. 2016;387(10025):1324–34.CrossRefPubMedGoogle Scholar
  91. 91.
    ••Sorajja P, Leon MB, Adams DH, Webb JG, Farivar RS. Transcatheter therapy for mitral regurgitation clinical challenges and potential solutions. Circulation. 2017;136(4):404–17. Interesting manuscript on the state of art of mitral interventionsCrossRefPubMedGoogle Scholar
  92. 92.
    Sorajja P, Maisano F. Percutaneous treatment for native mitral regurgitation. Prog Cardiovasc Dis. 2017;60(3):405–14.CrossRefPubMedGoogle Scholar
  93. 93.
    Monsefi N, Zierer A, Khalil M, Ay M, Beiras-Fernandez A, Moritz A, et al. Mitral valve surgery in six patients after failed MitraClip therapy. Tex Heart Inst J. 2014;41(6):609–12.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Bapat V. Mitral valve-in-ring: the good, the bad, and the ugly. EuroIntervention. 2016;11(10):1092–4.CrossRefPubMedGoogle Scholar
  95. 95.
    Sorajja P. Mitral Paravalvular Leak Closure. Interv Cardiol Clin. 2016;5(1):45–54.PubMedGoogle Scholar
  96. 96.
    Gillinov AM, Mihaljevic T, Javadikasgari H, Suri RM, Mick SL, Navia JL, et al. Early results of robotically assisted mitral valve surgery: analysis of the first 1000 cases. J Thorac Cardiovasc Surg. 2017;Google Scholar
  97. 97.
    Krapf C, Grimm M, Müller L. 3D Imaging for facilitation of totally endoscopic minimally invasive mitral valve surgery. Thoracic Cardiovasc Surgeon. 2016;64Google Scholar
  98. 98.
    JS. Transatrial sutureless adjustable mitral band: the next frontier 25th EACTS Congress; Lisbon 2011.Google Scholar
  99. 99.
    Maisano F, Falk V, Borger MA, Vanermen H, Alfieri O, Seeburger J, et al. Improving mitral valve coaptation with adjustable rings: outcomes from a European multicentre feasibility study with a new-generation adjustable annuloplasty ring system. Eur J Cardiothorac Surg. 2013;44(5):913–8.CrossRefPubMedGoogle Scholar
  100. 100.
    Andreas M, Doll N, Livesey S, Castella M, Kocher A, Casselman F, et al. Safety and feasibility of a novel adjustable mitral annuloplasty ring: a multicentre European experience. Eur J Cardiothorac Surg. 2016;49(1):249–54.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Matteo Saccocci
    • 1
  • Maurizio Taramasso
    • 1
  • Francesco Maisano
    • 1
  1. 1.Heart Center University Hospital of Zurich, Department of Cardiac Surgery - UniversitätsSpital ZürichZürichSwitzerland

Personalised recommendations